Baird analyst Michael Halloran downgrades Evoqua Water Techs (NYSE:AQUA) from Outperform to Neutral and maintains $49 price target.
What’s Going On With Life Science Company Evotec Stock Today?
Evotec SE (NASDAQ: EVO) joined forces with the Crohn's & Colitis Foundation to advance drug discovery and identify novel therapies for inflammatory bowel disease (IBD).